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Abstract
Background: Growth hormone (GH) has a strong positive influence on bone, stimulating both bone elongation
and increase in size. The aim of the study was to compare the effect of two different GH dosages on final height
and bone geometry in two groups of GH-deficient children.
Methods: We evaluated 121 children (86 m, 35f). Group 1 (77 patients) treated with GH at a mean dose of
0.16 mg/kg/week and group 2 (44 patients) at 0.3 mg/kg/week. Bone geometry was evaluated at final height from
a digitalized X-ray of the left hand considering the following parameters: metacarpal index (MI), cross-sectional area
(CSA), cortical area (CA) and medullary area (MA).
Results: At baseline, group 2 was shorter than group 1 (−1.54 vs −1.01 SDS; p < 0.005), while at final height there
was no difference. Height gain was significantly greater in group 2 than in group 1 (1.62 vs 1.13 SDS; p < 0.001).
Bone geometry: MI was significantly greater in group 2 (0.62 vs 0.55; p < 0.001) as well as CA (46.87 vs 42.69 cm2;
p < 0.005), while MA was significantly lower in group 2 (8.48 vs 11.65 cm2; p < 0.002).
Conclusion: Higher GH doses elicit a significantly greater statural gain and a greater bone cortical area.
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Background
Growth hormone (GH) exerts a strong positive influence
on bone by stimulating both bone elongation and in-
crease in size. It enhances the accrual of trabecular [1]
and cortical bone [2] up to the attainment of peak bone
mass in young adults [3]. GH stimulates longitudinal
bone growth and therefore statural growth, acting
mainly on the resting zone chondrocytes and inducing
local IGF-I production, which stimulates the clonal ex-
pansion of proliferating chondrocytes in an autocrine/
paracrine manner [4]. In addition, GH increases bone
size by IGF-I mediated subperiosteal bone growth [5–9].
We already showed in a previous paper [10] that higher
GH doses result in a greater height gain with a trend to-
ward larger bones at final height, leading eventually to
improved bone strength. In this study, we wanted to
confirm our previous findings by examining a larger
group of patients, similarly treated with two different
GH dosages.
Methods
This is a confirmatory study on the effect of two differ-
ent doses of GH on final height and bone geometry in a
large group of GH deficient children. The study was per-
formed in a University clinic and in a Regional Hospital.
Final height was measured in both centres by a wall-
mounted stadiometer and bone geometry was evaluated
on the X-ray obtained for evaluation of bone age. The
study protocol followed the ethical principles outlined
by the Helsinki Declaration. Adequate information about
the protocol supported the decision-making by the
parents.
Subjects
A total of 121 children (86 M and 35 F) affected by iso-
lated idiopathic GH-deficiency (GHD), who reached
their final height, were selected for the study. The diag-
nosis of GHD was based on auxological criteria and a
GH peak < 10 μg/l after at least 2 consecutive conven-
tional pharmacological tests. All children had a normal
pituitary on MRI, and were not affected by any cardio-
vascular, respiratory, renal, rheumatic diseases or by any
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other endocrine disorders. Seventy seven children
(57 M, 20 F) age 9.9 ± 3.6 were treated in Pavia with a
weekly rGH dosage of 0.16 mg/Kg for a mean period of
6.07 ± 3.2 years (group 1) while forty four children
(29 M, 15 F), age 10.3 ± 3.1 were treated in Bolzano with
a weekly rGH dosage of 0.3 mg/Kg for a mean period of
5.8 ± 2.7 years (group 2).
The male/female ratio in the two groups was not dif-
ferent (0.66 vs 0.74; NS). They were all regularly
followed-up until final height (bone age >15 years in
girls and >17 years in boys according to the method of
Greulich and Pyle [11]. Height and BMI were converted
to standard deviation score (SDS) according to the Ital-
ian Standards [12]. However, in order to also take the
patient’s genetic potential for growth into account,
height was expressed as parentally adjusted height-SDS,
i.e. the difference between height-SDS for chronological
age and target height–SDS (average height of both par-
ents plus 6.55 cm for boys and minus 6.55 cm for girls).
The difference between the parentally adjusted height-
SDS on attainment of adult stature and the one before
starting treatment was defined as relative height gain.
The auxological features of the patients are reported in
Table 1 (raw data) and Table 2 (parentally adjusted).
Bone geometry
We used the digitalised X-rays (Dicom files) taken for
the assessment of bone age, for the evaluation of bone
geometry. The following parameters were evaluated at
the level of the 2nd metacarpal bone at its narrowest
site, as previously described: outer (D) and inner (d)
diameter, metacarpal index (MI = D-d/D: mm), which is
a relative measure of the thickness of the 2nd metacarpal
cortical bone, total cross sectional area (TCSA: mm2),
cortical area (CA: mm2) and medullary endocortical area
(MA: mm2). TCSA, CA and MA are not directly mea-
sured with this technique, but calculated assuming that
the bone is cylindrical. Bone strength was calculated at
the metacarpus: it is dependent upon the material prop-
erty of the metacarpal bones (which cannot be directly
measured in vivo) and the cross-sectional moment of in-
ertia which is a function of the fourth power of the cor-
tical ring. By assuming a constant material property, a
Bending Breaking Resistance Index (BBRI-1) can be cal-
culated as follows: outer diameter (D) to the fourth
power minus inner diameter (d) to the fourth power di-
vided by D [D4-d4/D]. Furthermore, considering that
due to anatomical irregularities, the outer and the inner
circumferences are not exactly homogenenous, we tried
to overcome this problem by calculating the bone
strength using the corresponding areas instead of the di-
ameters (BBRI-2), according to the formula: (CSA2-
MA2)/√CSA).
Statistical analysis
The data were normally distributed and are reported as
mean ± SD. Student’s paired and unpaired t-test were
used to verify differences within and between groups,
after adjusting for height and sex. Simple correlations
were used to investigate the association between the dif-
ferent parameters. A P value of less than 0.05 indicated
statistical significance. The SAS Enterprise Guide
4.3statistical software (SAS Institute Inc. Cary, NC,
27513, USA) was used for these analyses.
Results
Auxology: parentally-adjusted height-SDS was signifi-
cantly higher in group 1 at the beginning of treatment
than in group 2 (−1.01 ± 0.83 vs −1.54 ± 1.14; p < 0.005),
while no difference between the 2 groups (0.11 ± 0.94 vs
0.15 ± 1.0;NS) was observed at the end of treatment.
Group 1 (−1.01 ± 0.83 vs 0.11 ± 0.94; p < 0.01) and group
2 (−1.54 ± 1.14 vs 0.15 ± 1.0; p < 0.001) significantly im-
proved their parentally-adjusted height-SDS, but height
gain was significantly higher in group 2 than in group 1
(1.13 ± 0.70 vs 1.62 ± 0.69; p < 0.001) (see Table 2).
Bone geometry: at final height, group 2 showed a
greater MI (0.55 ± 0.07 vs 0.62 ± 0.07; p < 0.001), a
greater CA (42.69 ± 8.39 vs 46.87 ± 9.39 mm2; p < 0.005)
but a significantly lower MA (11.65 ± 4.65 vs 8.48 ±
3.87 mm2; p < 0.002). There was no difference in total
cross sectional area (see Table 3 and Fig. 1). BBRI-1
(556.11 ± 167.69 vs 584.66 ± 177.30 mm3; NS), BBRI-2
(389.78 ± 116.57 vs 406.64 ± 123.32 mm3; NS).
Table 1 Clinical data
Number of
subjects
Age at the beginning
of treatment (yr)
BMI-SDS at the beginning
of treatment
Height SDS at the beginning
of treatment
Boys Girls
Group 1 77 9.89 ± 3.62 −1.5 ± 2.19 −1.76 ± 0.77 57 20
Group 2 44 10.29 ± 3.13 −0.23 ± 1.16 −1.97 ± 0.99 29 15
Table 2 Parentally adjusted height SDS and relative height
gains
Height 1 (SDS) Height 2 (SDS) GAIN
Group 1 −1.01 ± 0.83d 0.11 ± 0.94 1.13 ± 0.70
Group 2 −1.54 ± 1.14c, a 0.15 ± 1 1.62 ± 0.69b
aGroup 1 vs Group 2 p < 0.005
bGroup 1 vs Group 2 p < 0.001
cHeight 1 vs Height 2 p < 0.001
dHeight 1 vs Height 2 p < 0.01
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Correlations
CA was positively correlated with final height (r 0.40,
p < 0.001), height gain (r 0.22, p < 0.05), final BMI,
CSA (r 0.92, p < 0.0001) and BBRI. MI was positively
correlated with BMI at baseline (r 0.38, p < 0.0005)
and at final height (r 0.39, p < 0.0005) and negatively
with MA (r −0.82, p < 0.001) and CSA (r −0.24, p < 0.05).
MA was negatively correlated with BMI at baseline
(r −0.29, p < 0.01) and at final height (r −0.28, p < 0.01)
and positively with final height (r 0.31, p < 0.005) and
BBRI (r 0.57, p < 0.001).
Discussion
The major outcome of this study is the confirmation
that higher doses of GH elicit a significantly greater sta-
tural gain and improvement of the bone geometry. The
greater height gain achieved by the children receiving
the higher GH dosage is in agreement with previous re-
ports [10, 13–15], emphasizing the advantage of using
higher GH doses. Although 0.3 mg/Kg/week is a slightly
higher dose than that usually employed in isolated GHD,
it is in agreement with the recommendations of the GH
Research society [16].
Statural growth is mainly the result of bone elongation
under the influence of GH which, moreover, also stimu-
lates the width growth of the bones leading to an in-
creased size. In this study we were able to confirm the
positive influence of GH on bone, since the group of
children treated more intensively accrued more cortical
bone compared to the other group. This finding is also
supported by the positive correlations found between
cortical area and final height, height gain, cross sectional
area and BMI, which are all GH-dependent parameters.
In agreement with our findings, a previous study on
adults with growth hormone (GH) deficiency, also
showed the strong positive effect of GH treatment on
cortical bone, which was exerted by stimulating both
periosteal and endosteal bone apposition.
Furthermore, we found a smaller medullary area in
group 2 at final height (p < 0.002), suggesting that higher
dose of GH could induce a clearer effect on the endos-
teal side (the smaller the area, the clearer the effect) than
on the periosteal side of the bone.
MI and CA were therefore significantly higher in
group 2 (higher dose GH), strengthening the advantage
of using the higher GH dose. However, these geometrical
advantages, possibly due to the low number of subjects,
were not sufficient to produce a significant improvement
in BBRI, although a trend was observed.
One cannot exclude the possibility that another pos-
sible explanation for all these geometrical remarks might
be that the children in group 2 were significantly shorter
at baseline and so, presumably, they also had smaller
bones. In this case, the CSA might prove to be increased
more efficiently under higher GH dose. Unfortunately,
we were not able to calculate the relative gain in the dif-
ferent parameters of bone geometry in the two groups
since in many patients the X-rays taken at the beginning
of the treatment with GH were not available. Another
possible explanation might have been an overrepresenta-
tion of females in group 2, since females are known to
have a greater endocortical acquisition during puberty.
The male/female ratio in the two groups was however
not different and differences in sex and height have been
taken into account in statistical analysis.
In our study we did not measure for technical reasons
bone mineral density at the lumbar spine, which is an
Table 3 Bone geometry and bone strength in the two groups
MI CA (mm2) MA (mm2) CSA (mm2) BBRI-1 (mm3) BBRI-2 (mm3)
Group 1 0.55 ± 0.07 42.69 ± 8.39 11.65 ± 4.65 54.34 ± 11.66 556.11 ± 167.69 389.78 ± 116.57
Group 2 0.62 ± 0.07a 46.87 ± 9.39b 8.48 ± 3.87c 55.35 ± 11.14 584.66 ± 177.30 406.64 ± 123.32
aGroup 1 vs Group 2 p < 0.001
bGroup 1 vs Group 2 p < 0.005
cGroup 1 vs Group 2 p < 0.002
Group 1 Group 2 
Fig. 1 Bone geometry in the two groups
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important marker of peak bone mass, however, bone
geometry measured at metacarpal level is strongly re-
lated with bone status in other sites [17–19].
One limit of this paper is the fact that the diagnosis of
GHD was based on a level of GH after pharmacological
stimulation of less than 10 μg/l while now, in Italy, a
value of 8 μg/l is considered as more appropriate. This
might have allowed the inclusion of some short normal
children, according to the new criteria.
Conclusion
We confirm the beneficial effects of larger doses of
growth hormone on both height gain and bone
accretion.
The study protocol followed the ethical principles out-
lined by the Helsinki Declaration. Adequate information
about the protocol supported the decision-making by
the parents.
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